July 15, 2019 / 6:26 AM / a month ago

AstraZeneca's Farxiga fails to get FDA approval for Type-1 diabetes

July 15 (Reuters) - British drugmaker AstraZeneca Plc said on Monday the U.S. Food and Drug Administration declined to approve its diabetes treatment, Farxiga, for use as a supplement to insulin in adults with Type-1 diabetes.

The company said the regulator had issued a complete response letter, declining its application for using Farxiga in the new indication.

Farxiga is already approved in the United States for use in Type-2 diabetes. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below